NO328085B1 - Anvendelse av staurosporinderivater for fremstilling av et medikament for behandling av okulaere neovaskulaere sykdommer - Google Patents

Anvendelse av staurosporinderivater for fremstilling av et medikament for behandling av okulaere neovaskulaere sykdommer Download PDF

Info

Publication number
NO328085B1
NO328085B1 NO20012490A NO20012490A NO328085B1 NO 328085 B1 NO328085 B1 NO 328085B1 NO 20012490 A NO20012490 A NO 20012490A NO 20012490 A NO20012490 A NO 20012490A NO 328085 B1 NO328085 B1 NO 328085B1
Authority
NO
Norway
Prior art keywords
treatment
mice
prevention
retinal
drug
Prior art date
Application number
NO20012490A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012490D0 (no
NO20012490L (no
Inventor
Jeanette Marjorie Wood
Romulus Kimbro Brazzell
Peter Anthony Campochiaro
Frances Elizabeth Kane
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20012490D0 publication Critical patent/NO20012490D0/no
Publication of NO20012490L publication Critical patent/NO20012490L/no
Publication of NO328085B1 publication Critical patent/NO328085B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20012490A 1998-11-23 2001-05-21 Anvendelse av staurosporinderivater for fremstilling av et medikament for behandling av okulaere neovaskulaere sykdommer NO328085B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19867798A 1998-11-23 1998-11-23
PCT/EP1999/008987 WO2000030651A1 (en) 1998-11-23 1999-11-22 Use of staurosporine derivatives for treating ocular neovascular diseases

Publications (3)

Publication Number Publication Date
NO20012490D0 NO20012490D0 (no) 2001-05-21
NO20012490L NO20012490L (no) 2001-06-25
NO328085B1 true NO328085B1 (no) 2009-11-30

Family

ID=22734344

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012490A NO328085B1 (no) 1998-11-23 2001-05-21 Anvendelse av staurosporinderivater for fremstilling av et medikament for behandling av okulaere neovaskulaere sykdommer

Country Status (19)

Country Link
EP (1) EP1131073B1 (es)
JP (2) JP2002530342A (es)
KR (1) KR100698449B1 (es)
CN (1) CN1172673C (es)
AT (1) ATE252387T1 (es)
AU (1) AU761092B2 (es)
BR (1) BR9915569A (es)
CA (1) CA2348890C (es)
DE (1) DE69912304T2 (es)
DK (1) DK1131073T3 (es)
ES (1) ES2211197T3 (es)
HK (1) HK1040182A1 (es)
ID (1) ID29970A (es)
IL (2) IL142757A0 (es)
NO (1) NO328085B1 (es)
NZ (1) NZ511559A (es)
PT (1) PT1131073E (es)
WO (1) WO2000030651A1 (es)
ZA (1) ZA200103925B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
WO2004009056A1 (en) * 2002-07-23 2004-01-29 Novartis Ag Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
CN101580515B (zh) * 2008-05-16 2011-06-08 上海医药工业研究院 一种星形孢菌素提取纯化的方法
EP2406250B1 (en) 2009-03-11 2015-08-12 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN102924479A (zh) * 2011-08-09 2013-02-13 山东鲁北药业有限公司 一种星孢菌素类衍生物的半合成方法
US9345705B2 (en) 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
ME02925B (me) 2012-11-28 2018-04-20 Merck Sharp & Dohme Kompozicije i postupci za liječenje kancera

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
CA2138644A1 (en) * 1992-07-08 1994-01-20 Bert M. Glaser Method of treating ophthalmic disorders using tgf-.beta.
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
AU2066797A (en) * 1996-03-21 1997-10-10 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
EP1061913B1 (en) * 1998-03-13 2007-06-27 The Johns Hopkins University School Of Medicine The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy

Also Published As

Publication number Publication date
IL142757A0 (en) 2002-03-10
CN1172673C (zh) 2004-10-27
BR9915569A (pt) 2001-08-14
JP2011088938A (ja) 2011-05-06
CN1328462A (zh) 2001-12-26
ID29970A (id) 2001-10-25
PT1131073E (pt) 2004-03-31
ATE252387T1 (de) 2003-11-15
ES2211197T3 (es) 2004-07-01
CA2348890A1 (en) 2000-06-02
EP1131073B1 (en) 2003-10-22
NO20012490D0 (no) 2001-05-21
NZ511559A (en) 2004-01-30
DK1131073T3 (da) 2004-02-02
CA2348890C (en) 2009-05-12
KR100698449B1 (ko) 2007-03-23
DE69912304D1 (de) 2003-11-27
NO20012490L (no) 2001-06-25
AU761092B2 (en) 2003-05-29
JP2002530342A (ja) 2002-09-17
IL142757A (en) 2007-07-04
ZA200103925B (en) 2002-07-25
AU1506600A (en) 2000-06-13
DE69912304T2 (de) 2004-07-22
EP1131073A1 (en) 2001-09-12
HK1040182A1 (en) 2002-05-31
WO2000030651A1 (en) 2000-06-02
KR20010078398A (ko) 2001-08-20

Similar Documents

Publication Publication Date Title
JP2011088938A (ja) 眼血管新生疾患の処置のためのスタウロスポリン誘導体の使用
BG99213A (bg) Фармацевтичен състав за лечение на глаукома
KR20190134588A (ko) 다중 키나아제 억제제 및 안구 섬유증에의 사용
JP5801324B2 (ja) 緑内障及び高眼圧症の治療のためのシチコリン
US20100190734A1 (en) Method of treating dry eye disease with azithromycin
US6214819B1 (en) Method for treating ocular neovascular diseases
JP2016514123A (ja) ジピリダモールを用いる眼疾患の治療において使用するための組成物
JP2004331502A (ja) 視神経細胞保護剤
EP2266559A1 (en) Therapeutic agent for ophthalmic disease
KR20170123502A (ko) 콜라겐 및 색소 상피성 인자를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물
AU2002309280A1 (en) Agent for protection of retinal neurons
WO2023176720A1 (ja) 網膜血管拡張剤及び医薬組成物
JP2005521681A (ja) 尿素および尿素誘導体を使用した眼科疾患の治療方法
JP4393863B2 (ja) 視神経細胞保護剤
Navarro-Partida et al. Safety and Tolerability of Topical Ophthalmic Triamcinolone Acetonide-Loaded Liposomes Formulation and Evaluation of Its Biologic Activity in Patients with Diabetic Macular Edema. Pharmaceutics 2021, 13, 322
US20060172977A1 (en) Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage
Taoa et al. Intravitreous Delivery of Αb-Crystallin Ameliorates N-Methyl-N-Nitrosourea Induced Photoreceptor Degeneration in Mice: An in vivo and ex vivo Study
US9308165B2 (en) Composition for treating ocular effects of diabetes
Thygesen Treatment of Glaucoma with or without Medications Lowering Intraocular Pressure: Options and Relevant General Health Issues
JP2005097137A (ja) 糖尿病性網膜症の予防又は治療剤
MXPA01005152A (es) Uso de derivados de estaurosporina para el tratamiento de enfermedades neovasculares oculares
WO2000067740A9 (en) Aminoguanidine for treating glaucomatous optic neuropathy

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees